Changes in Beneficial Ownership · 4
Minerva Neurosciences, Inc
NERVNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-06052026_060613.xml
Filing details
- Report period
- 2026-06-03
- Issuer
- Minerva Neurosciences, Inc.
- Issuer CIK
- 0001598646
- Trading symbol
- NERV
Reporting owner 1
- Name
- Ahlholm Frederick W
- Reporting owner CIK
- 0001405279
- Relationship
- Officer
- Officer title
- SVP, CFO and Secretary
- Address
- C/O MINERVA NEUROSCIENCES, INC., 1500 DISTRICT AVENUE, BURLINGTON, MA, 01803
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | 4.68 | 2026-06-03 | A · Form 4 | 680,000 | A | 0 | [F1] | 2036-06-02 | Common Stock | 680,000 | 680,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The option vests 25% on June 3, 2027 and then in equal quarterly installments over 3 years thereafter.↩ 1
Signature 1
- Signed
- /s/ Frederick Ahlholm
- Date
- 2026-06-05
Company context
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is conducting a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.